In an interview with PharmaShots, Dr. Andreas Harstrick, Chief Medical Officer at Affimed shared his views on updated clinical data related to their lead innate cell engager AFM13 at the […]readmore
Tags : Affimed
Shots: The collaboration is for development and commercialization of novel NK cell engager-based immunotherapeutics to treat multiple cancers Affimed’s will use its ROCK platform (Redirected Optimized Cell Killing) to develop […]readmore